Browse > Article
http://dx.doi.org/10.4333/KPS.2003.33.2.099

Effect of Crystal Form on Dissolution of Prednisolone  

Sohn, Young-Taek (College of Pharmacy, Duksung Women's University)
Do, Eui-Sun (College of Pharmacy, Duksung Women's University)
Publication Information
Journal of Pharmaceutical Investigation / v.33, no.2, 2003 , pp. 99-103 More about this Journal
Abstract
Four different crystal forms of prednisolone, two polymorphic forms and two pseudopolymorphic forms, were obtained by the recrystallization from different organic solvents under varying conditions. The isolated crystal forms were characterized by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and X-ray powder diffraction (XRD). Form 1 was the most stable form that had the highest melting point and melt at $250.1^{\circ}C$. Form 2 was a monohydrate and Form 3 was a methanol solvate. The endothermic peak of Form 4 was shown at $230.2^{\circ}C$. When stored at different relative humidity over the period of 3 months, all of the modifications did not undergo transformation. The dissolution patterns of these four modifications were also checked in distilled water at $37{\pm}0.5^{\circ}C$, for 120 minutes. The dissolution rate of Form 4 was highest and those of Form 3, Form 2, Form 1 followed. Form 2, Form 3 and Form 4 had higher dissolution rate than Form 1.
Keywords
Prednisolone; Polymorphism; Pseudopolymorphism; Transformation; Recrystallization; DSC; TGA; XRD; Dissolution;
Citations & Related Records
연도 인용수 순위
  • Reference
1 N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa, Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-41 (1989).
2 E. F. Fiese and T. A. Hagen : Preformulation : In Theory and Practice of Industrial Pharmacy, L. Lachman, H. A. Lieberman and J. L. Kanig(Eds.), 3rd Edition, Lea and Febiger, Philadelphia, pp171 (1986)
3 Y. T. Sohn, Dissolution and transformation of crystal form of piroxicam, Yakhak Hoeji, 40, 513-521 (1996)
4 Y. T. Sohn and B. Y. Urn, Dissolution of crystal form of glibenclamide, J. Kor. Pharm. Sci., 27, 233-239 (1997)
5 Y. T. Sohn, J. K. Lee and W. B. 1m, Polymorphism of clarithromycin, Arch. Pharm. Res., 23, 381-384 (2000)   DOI   ScienceOn
6 Y. T. Sohn, Pharmaceutical application of polymorphism, Pharmacon, 21, 500-516 (1981)
7 B. D. Sharma, Allotropes and polymorphs, J. Chem. Educ., 64,404-407 (1987)   DOI
8 J. Bemstein, Conformational polymorphism, Stud. Org. Chem. (Amsterdam), 32(Org. Solid Statd Chem.), 471-518 (1987)
9 M. Kitamura, Polymorphism in crystallization, Kagaku kogaku, 55, 263-264 (1991)
10 J. Haleblian and W. McCrone, Pharmaceutical applications of polymorphism, J. Pharm. Sci., 58, 911-929 (1969).   DOI
11 W. C. Kind, P. Varlashkin and C. Li, The applicability of powder x-ray diffraction to the quantification of drug substance polymorphs using a model organic system, Powder Diffr., 8, 180-187 (1993)   DOI
12 J. Bernstein, Polymorphism and the investigation of structure-property relations in organic solids, Int. Union Crystallogr. Crystallogr. Syrnp. 4 (Org. Cryst. Chern.), 6-26(1991)
13 F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Theor. Chern., 69 (Struct. Prop. Mol. Cryst.), 211-234 (1990)
14 D. E. Wouster and W.Tailor Jr., Dissolution kinetics of certain crystalline forms of prednisolone, J. Pharm. Sci., 54, 670-676(1965)   DOI
15 Y. T. Sohn and E. H. Lee, Crystal form of cephazoline sodium hydrate, Yakhak Hoeji, 40, 306-310 (1996)
16 Y. T. Sohn and S. H. Park, Effects of crystal modification of cephalothin sodium on dissolution and stability, Yakhak Hoeji, 41, 321-327 (1997)
17 Y. T. Sohn and J. S. Kim, Effect of crystal form on dissolution of cephradin, J. Kor. Pharm. Sci., 28, 115-119 (1998)
18 A. Bauer-Brandl and Y. T. Sohn, Crystal modifications of cimetidine: Characterization and evaluation for manufacturing of dosage forms, Eur. J. Pharm. Biopharm., 40(Suppl.), 6S(1994)
19 Y. T. Sohn and H. K. Kim, Dissolution of crystal form of cephotaxime sodium, J. Kor. Pharm. Sci., 28, 81-85 (1998)
20 Y. T. Sohn and I. J. Chun, Crystal form of cefaclor, J Kor. Pharm. sa, 30, 201-206 (2000)
21 Y. T. Sohn, Effect of polymorphism on bioavailability of amoxycillin, Yakhak Hoeji., 39, 438-443 (1995)
22 Y. T. Sohn, M. S. Park and S. K. Kwon, Polymorphism of biphenyldimethyldicarboxy late, J. Kor. Pharm. Sci., 26, 193199(1996).
23 Y. T. Sohn and S. H. lung, Effect ofcrystal form on dissolution and stability of droperidol, Yakhak Hoeji, 40, 375-381 (1996)
24 A. Burger, Zur Interpretation von Polymorphie-untersuchungen, Acta Pharm. Technol., 28, 1-20 (1982)
25 A. Burger and K. T. Koller, Polymorphism and pseudopolymorphism on nifedifine, Sci. Pharm., 64, 293-301 (1996)
26 A. David, E. Balogh, G. Csoka and I. Racz, Methodological aspects of examination of the polymorphism of vincristine sulfate, Sci. Pharm., 64, 311-318 (1996).
27 M. R. Caira, M. Zanol, T. Peveri, A. Gazzaniga and F. Giordano, Structural characterization of two polymorphic forms of piroxicam pivalate, J. Pharm. Sci., 87, 1608-1614 (1998)   DOI   ScienceOn